Trial Profile
STA9090: Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2016
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Capecitabine
- Indications Rectal cancer
- Focus Therapeutic Use
- 19 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 May 2015 Interim results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 28 May 2015 According to a Synta Pharmaceuticals media release, data from this trial will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.